Debates

This is half of a two-part debate — read the opposing argument. Esophageal symptoms are common and affect at least a quarter of the population. There are a multitude of diagnostic tests available, but no true gold standard and each test is complementary.  Endoscopy allows direct visualization of the mucosa, biopsy acquisition and potential dilation […]

Debates

This is half of a two-part debate — read the opposing argument. Preamble to this article:  I did not volunteer to write this opinion paper, but was asked by the outgoing editor, Dr. Gary Falk. Why, I’m not sure, because I don’t have this technology in our Esophageal Center at the University of South Florida. […]

Debates

This is half of a two-part debate — read the opposing argument. Recurrent bleeding, along with advanced age and medical co-morbidities, is an independent predictor of mortality in patients with upper gastrointestinal (GI) hemorrhage. Although we as endoscopists cannot alter the patient’s age or their comorbidities, we may be able to reduce the risk of […]

Debates

This is half of a two-part debate — read the opposing argument. Why use Doppler endoscopic probe (DEP) in the management of severe non-variceal gastrointestinal hemorrhage (NVUGIH)? The fundamental reason is that DEP gives endoscopists a new dimension to help them treat patients: the ability to monitor arterial blood flow underneath stigmata of recent hemorrhage […]

Debates

This is half of a two-part debate — read the opposing argument. For most individuals with gastroesophageal reflux, treatment with antisecretory medication yields excellent symptom relief. However, medical management fails in a subset of patients with more severe symptoms, and antireflux surgery should be considered. Traditionally the procedure of choice has been a 360° (Nissen) […]

ContributeDebates

This is half of a two-part debate — read the opposing argument.  Following the introduction of infliximab in 1998, two additional tumor necrosis factor antagonists (i.e., adalimumab, certolizumab pegol), the anti- integrin vedolizumab and ustekinumab (a monoclonal directed to interleukin 12 and 23) were approved for the management of inflammatory bowel disease. Biologics have greatly […]

Debates

This is half of a two-part debate — read the opposing argument.  The safety and effectiveness of anti–tumor necrosis factor (TNF) therapy for the treatment of inflammatory bowel disease (IBD) has been well established for decades. Therefore, introducing anti-TNF biosimilars to the marketplace does not represent a new mode of treatment for patients with IBD, […]